

DAFTAR PUSTAKA

1. Ahmed, S. *et al.* (2014) 'Advances in the management of colorectal cancer: From biology to treatment', *International Journal of Colorectal Disease*, 29(9), pp. 1031–1042. doi: 10.1007/s00384-014-1928-5.
2. Ajouz, H., Mukherji, D. and Shamseddine, A. (2014) 'Secondary bile acids: An underrecognized cause of colon cancer', *World Journal of Surgical Oncology*, 12(1), pp. 1–5. doi: 10.1186/1477-7819-12-164.
3. Ali, M. A. M. *et al.* (2021) 'Matrix metalloproteinase-2 mediates ribosomal RNA transcription by cleaving nucleolar histones', *FEBS Journal*, 288(23), pp. 6736–6751. doi: 10.1111/febs.16061.
4. Alzahrani, S. M., Al Doghaither, H. A. and Al-Ghafar, A. B. (2021) 'General insight into cancer: An overview of colorectal cancer (review)', *Molecular and Clinical Oncology*, 15(6). doi: 10.3892/MCO.2021.2433.
5. Amersi, F., Agustin, M. and Ko, C. Y. (2006) 'Colorectal cancer: Epidemiology and health services research', *Surgical Oncology Clinics of North America*, 15(1), pp. 21–37. doi: 10.1016/j.soc.2005.08.003.
6. Annaházi, A. *et al.* (2013) 'Fecal MMP-9: A new noninvasive differential diagnostic and activity marker in ulcerative colitis', *Inflammatory Bowel Diseases*, 19(2), pp. 316–320. doi: 10.1002/ibd.22996.
7. Annaházi, A. *et al.* (2016) 'A pilot study on faecal MMP-9: A new noninvasive diagnostic marker of colorectal cancer', *British Journal of Cancer*, 114(7), pp. 787–792. doi: 10.1038/bjc.2016.31.
8. Aran, V. *et al.* (2016) 'Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality', *Clinical Colorectal Cancer*, 15(3), pp. 195–203. doi: 10.1016/j.clcc.2016.02.008.
9. Araújo, R. F. *et al.* (2015) 'Prognostic and diagnostic implications of MMP-2, MMP-9, and VEGF- α expressions in colorectal cancer', *Pathology Research and Practice*, 211(1), pp. 71–77. doi: 10.1016/j.prp.2014.09.007.
10. Arnold, M. *et al.* (2017) 'Global patterns and trends in colorectal cancer incidence and mortality', *Gut*, 66(4), pp. 683–691. doi: 10.1136/gutjnl-2015-310912.

11. Aykan, N. F. (2015) 'Red meat and colorectal cancer', *Oncology Reviews*, 9(1), pp. 38–44. doi: 10.4081/oncol.2015.288.
12. Banias, L. *et al.* (2022) 'From Dukes-MAC Staging System to Molecular Classification: Evolving Concepts in Colorectal Cancer', *International Journal of Molecular Sciences*, 23, p. 9455.
13. Barták, B. K. *et al.* (2017) 'Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples', *Epigenetics*, 12(9), pp. 751–763. doi: 10.1080/15592294.2017.1356957.
14. Beauty, V. *et al.* (2018) *The Role of faecal matrix metalloproteinase-9 in the diagnosis of patients with suspected colorectal cancer in Cipto Mangunkusumo National General Hospital, Universitas Indonesia*. Available at: <http://dx.doi.org/10.1038/s41467-020-14526-3>
https://www.oecd-ilibrary.org/finance-and-investment/african-central-government-debt-2013/supplementary-information_acgd-2013-23-en
<http://dx.doi.org/10.1038/s41467-019-10038-x>
<http://dx.doi.org/10.1038/s>.
15. Bertero, L. *et al.* (2018) 'Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria—What has changed and why?', *Virchows Archiv*, 472(4), pp. 519–531. doi: 10.1007/s00428-017-2276-y.
16. Bevan, R. and Rutter, M. D. (2018) 'Colorectal Cancer Screening — Who , How , and When ?', *Clin Endosc*, 51, pp. 37–49.
17. Brar, B. *et al.* (2021) 'Nanotechnology in Colorectal Cancer for Precision Diagnosis and Therapy', *Frontiers in Nanotechnology*, 3(September), pp. 1–21. doi: 10.3389/fnano.2021.699266.
18. Bray, F. *et al.* (2015) 'Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration', *International Journal of Cancer*, 137(9), pp. 2060–2071. doi: 10.1002/ijc.29670.
19. Bronchud, M. *et al.* (2000) 'Molecular Basis of Cancer', *The Lancet*, 356(Oct 14), p. 2000. doi: 10.1016/s0140-6736(05)74283-5.

20. Brown, K. G. M. *et al.* (2019) 'Management of colorectal cancer', *The BMJ*, 366(August), pp. 1–7. doi: 10.1136/bmj.l4561.
21. Brzacki, V. *et al.* (2019) 'Diabetes Mellitus: a Clinical Condition Associated with Metabolic Syndrome and Colorectal Cancer Risk', *Current Pharmacology Reports*, 5(4), pp. 205–209. doi: 10.1007/s40495-019-00183-8.
22. Carethers, J. M. and Doubeni, C. A. (2020) 'Causes of Socioeconomic Disparities in Colorectal Cancer and Intervention Framework and Strategies', *Gastroenterology*, 158(2), pp. 354–367. doi: 10.1053/j.gastro.2019.10.029.
23. Carr, P. R. *et al.* (2018) 'Lifestyle factors and risk of sporadic colorectal cancer by microsatellite instability status: A systematic review and meta-analyses', *Annals of Oncology*, 29(4), pp. 825–834. doi: 10.1093/annonc/mdy059.
24. Cascella, M. *et al.* (2018) 'Dissecting the mechanisms and molecules underlying the potential carcinogenicity of red and processed meat in colorectal cancer (CRC): An overview on the current state of knowledge', *Infectious Agents and Cancer*, 13(1), pp. 1–8. doi: 10.1186/s13027-018-0174-9.
25. Casciato, D. and Territo, M. (2012) *Manual of Clinical Oncology*. 7th edn. Philadelphia: Lippincott Williams & Wilkins.
26. Chan, D. S. M. *et al.* (2011) 'Red and processed meat and colorectal cancer incidence: Meta-analysis of prospective studies', *PLoS ONE*, 6(6). doi: 10.1371/journal.pone.0020456.
27. Cheng, Y., Ling, Z. and Li, L. (2020) 'The Intestinal Microbiota and Colorectal Cancer', *Frontiers in Immunology*, 11(November), pp. 1–13. doi: 10.3389/fimmu.2020.615056.
28. Chu, D. *et al.* (2012) 'Matrix metalloproteinase-9 is associated with relapse and prognosis of patients with colorectal cancer', *Annals of Surgical Oncology*, 19(1), pp. 318–325. doi: 10.1245/s10434-011-1686-3.
29. Cisterna, B. A. *et al.* (2016) 'Targeted nanoparticles for colorectal cancer', *Nanomedicine*, 11(18), pp. 2443–2456. doi: 10.2217/nnm-2016-0194.
30. Daly, M. C. and Paquette, I. M. (2019) 'Surveillance, Epidemiology, and End Results (SEER) and SEER-Medicare Databases: Use in Clinical Research for Improving Colorectal Cancer Outcomes', *Clinics in Colon and Rectal Surgery*,

32(1), pp. 61–68. doi: 10.1055/s-0038-1673355.

31. Ferlay, J. *et al.* (2021) ‘Cancer statistics for the year 2020: An overview’, *International Journal of Cancer*, 149(4), pp. 778–789. doi: 10.1002/ijc.33588.
32. Fleming, M. *et al.* (2012) ‘Colorectal carcinoma: Pathologic aspects’, *Journal of Gastrointestinal Oncology*, 3(3), pp. 153–173. doi: 10.3978/j.issn.2078-6891.2012.030.
33. Ford, A. C. *et al.* (2008) ‘Diagnostic utility of alarm features for colorectal cancer: Systematic review and meta-analysis’, *Gut*, 57(11), pp. 1545–1552. doi: 10.1136/gut.2008.159723.
34. Fouad, A. M. and Elzawawy, A. M. (2020) ‘Prognostic Value of the Matrix Metalloproteinase-9 and Its Relation to Clinicopathological Features in Women with Invasive Breast Cancer’, pp. 448–461. doi: 10.4236/jct.2020.117038.
35. Gandomani, H. S. *et al.* (2017) ‘Colorectal cancer in the world: incidence, mortality and risk factors’, *Biomedical Research and Therapy*, 4(10), p. 1656. doi: 10.15419/bmrat.v4i10.372.
36. Groblewska, M., Mroczo, B. and Szmitkowski, M. (2010) ‘The role of selected matrix metalloproteinases and their inhibitors in colorectal cancer development’, *Postepy Hig Med Dosw*, 64, pp. 22–30. Available at: <http://www.phmd.pl/fulltxt.php?ICID=903908>.
37. Gupta, S. *et al.* (2020) ‘Recommendations for Follow-Up after Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer’, *American Journal of Gastroenterology*, 115(3), pp. 415–434. doi: 10.14309/ajg.0000000000000544.
38. Guraya, S. (2014) ‘Chemopreventive role of vitamin D in colorectal carcinoma’, *Journal of Microscopy and Ultrastructure*, 2(1), p. 1. doi: 10.1016/j.jmau.2013.09.001.
39. Hammond, W. A., Swaika, A. and Mody, K. (2016) ‘Pharmacologic resistance in colorectal cancer: A review’, *Therapeutic Advances in Medical Oncology*, 8(1), pp. 57–84. doi: 10.1177/1758834015614530.
40. Han, Y. D. *et al.* (2019) ‘Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA’, *Clinical Epigenetics*, 11(1),

pp. 1–11. doi: 10.1186/s13148-019-0642-0.

41. Hashimoto, Y., Zumwalt, T. J. and Goel, A. (2016) 'DNA methylation patterns as noninvasive biomarkers and targets of epigenetic therapies in colorectal cancer', *Epigenomics*, 8(5), pp. 685–703. doi: 10.2217/epi-2015-0013.
42. Hayman, C. V and Vyas, D. (2021qqw) 'Screening colonoscopy : The present and the future', *World Journal of Gastroenterology*, 27(3), pp. 233–239. doi: 10.3748/wjg.v27.i3.233.
43. Herszényi, L. *et al.* (2012) 'The Behavior of matrix metalloproteinases and their inhibitors in colorectal cancer', *International Journal of Molecular Sciences*, 13(10), pp. 13240–13263. doi: 10.3390/ijms131013240.
44. Hnatyszyn, A. *et al.* (2019) 'Colorectal carcinoma in the course of inflammatory bowel diseases', *Hereditary Cancer in Clinical Practice*, 17(1), pp. 1–9. doi: 10.1186/s13053-019-0118-4.
45. Hossain, M. S. *et al.* (2022) 'Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies', *Cancer*, 14(1732), pp. 1–25.
46. Huang, H. (2018) 'Matrix metalloproteinase-9 (MMP-9) as a cancer biomarker and MMP-9 biosensors: Recent advances', *Sensors (Switzerland)*, 18(10), pp. 5–7. doi: 10.3390/s18103249.
47. IARC (2018) *Handbook of Cancer Prevention Vol. 17 - Colorectal Cancer Screening*, *Journal of Global Oncology*. doi: 10.1200/jgo.18.17700.
48. Issa, I. A. and Nouredine, M. (2017) 'Colorectal cancer screening: An updated review of the available options', *World Journal of Gastroenterology*, 23(28), pp. 5086–5096. doi: 10.3748/wjg.v23.i28.5086.
49. Jeo, W. and Subrata, F. (2020) 'The Survival Rate of Colorectal Cancer in dr. Cipto Mangunkusumo Hospital', *The New Ropanasuri : Journal of Surgery*, 5(2), pp. 13–17. doi: 10.7454/nrjs.v5i2.1081.
50. Johdi, N. A. and Sukor, N. F. (2020) 'Colorectal Cancer Immunotherapy: Options and Strategies', *Frontiers in Immunology*, 11(September), pp. 1–18. doi: 10.3389/fimmu.2020.01624.
51. Kang, J. C. *et al.* (2010) 'Intratumoral macrophage counts correlate with tumor progression in colorectal cancer', *Journal of Surgical Oncology*, 102(3), pp.

242–248. doi: 10.1002/jso.21617.

52. Kapoor, C. *et al.* (2016) ‘Seesaw of matrix metalloproteinases (MMPs)’, *Journal of Cancer Research and Therapeutics*, 12(1), pp. 28–35. doi: 10.4103/0973-1482.157337.
53. Keum, N. N. and Giovannucci, E. (2019) ‘Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies’, *Nature Reviews Gastroenterology and Hepatology*, 16(12), pp. 713–732. doi: 10.1038/s41575-019-0189-8.
54. Kim, K. *et al.* (2016) ‘MMP-9 facilitates selective proteolysis of the histone H3 tail at genes necessary for proficient osteoclastogenesis’, *Genes and Development*, 30(2), pp. 208–219. doi: 10.1101/gad.268714.115.
55. Kolligs, F. T. (2016) ‘Diagnostics and epidemiology of colorectal cancer’, *Visceral Medicine*, 32(3), pp. 158–164. doi: 10.1159/000446488.
56. Kranenburg, O., Speeten, K. van der and Hingh, I. de (2021) ‘Peritoneal Metastases From Colorectal Cancer: Defining and Addressing the Challenges’, *Frontiers in Oncology*, 11(March), pp. 1–11. doi: 10.3389/fonc.2021.650098.
57. Krasteva, N. and Georgieva, M. (2022) ‘Promising Therapeutic Strategies for Colorectal Cancer Treatment Based on Nanomaterials’, *Pharmaceutics*, 14(6), pp. 1–38. doi: 10.3390/pharmaceutics14061213.
58. Kristina, S. A., Ayu Linda Permitasari, N. P. and Ahsan, A. (2019) ‘The Premature Mortality Cost of Cancers Attributable to Secondhand Smoking in Indonesia’, *Asian Pacific Journal of Cancer Care*, 4(4), pp. 107–112. doi: 10.31557/apjcc.2019.4.4.107-112.
59. Lawler, M. *et al.* (2019) *Colorectal Cancer*. Sixth Edit, *Abeloff’s Clinical Oncology*. Sixth Edit. Elsevier Inc. doi: 10.1016/B978-0-323-47674-4.00074-8.
60. Lech, G. *et al.* (2016) ‘Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances’, *World Journal of Gastroenterology*, 22(5), pp. 1745–1755. doi: 10.3748/wjg.v22.i5.1745.
61. Leggett, B. and Whitehall, V. (2010) ‘Role of the Serrated Pathway in Colorectal Cancer Pathogenesis’, *Gastroenterology*, 138(6), pp. 2088–2100. doi: 10.1053/j.gastro.2009.12.066.

62. Lubbe, W. J. *et al.* (2006) 'Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer', *Clinical Cancer Research*, 12(6), pp. 1876–1882. doi: 10.1158/1078-0432.CCR-05-2686.
63. Lusikooy, R. (2017) *Faktor Resiko Terjadinya Kanker Kolorektal di Indonesia*. Hasanuddin University.
64. Lwanga, S. K. and Lemeshow, S. (1991) *Sample Size Determination in Health Studies: A Practical Manual.*, *Journal of the American Statistical Association*. doi: 10.2307/2290547.
65. Ma, Y. *et al.* (2018) 'Type 2 diabetes and risk of colorectal cancer in two large U.S. prospective cohorts', *British Journal of Cancer*, 119(11), pp. 1436–1442. doi: 10.1038/s41416-018-0314-4.
66. Makmun, D. *et al.* (2014) 'Changing trends in gastrointestinal malignancy in Indonesia: The Jakarta experience', *Journal of Cancer Research & Therapy*, 2(9), pp. 160–168. doi: 10.14312/2052-4994.2014-24.
67. Mármol, I. *et al.* (2017) 'Colorectal carcinoma: A general overview and future perspectives in colorectal cancer', *International Journal of Molecular Sciences*, 18(1). doi: 10.3390/ijms18010197.
68. Mondal, S. *et al.* (2020) 'Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview', *European Journal of Medicinal Chemistry*, 194, p. 112260. doi: 10.1016/j.ejmech.2020.112260.
69. Morgan, E. *et al.* (2020) 'Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN', *Gut*, 72(2).
70. Mudatsir *et al.* (2023) 'Relationship between metalloproteinase-9 (MMP-9) expression and clinicopathology in colorectal cancer: a cross-sectional study', *Annals of Medicine & Surgery*, 85(9), pp. 4277–4282. doi: 10.1097/ms9.0000000000000892.
71. Nagtegaal, I. D. *et al.* (2020) 'The 2019 WHO classification of tumours of the digestive system', *Histopathology*, 76(2), pp. 182–188. doi: 10.1111/his.13975.
72. National Cancer Institute (2022) 'Financial Burden of Cancer Care', *Cancer Trends Progress Report*, Updated Ap. Available at: https://progressreport.cancer.gov/after/economic_burden#field_most_recent_

estimates.

73. Nguyen, T. T. *et al.* (2018) 'Role of bile acids in colon carcinogenesis', *World J Clin Cases*, 9(9), pp. 157–164.
74. Nojadeh, J. N., Sharif, S. B. and Sakhinia, E. (2018) 'Microsatellite instability in colorectal cancer', *EXCLI Journal*, 17, pp. 159–168. doi: 10.17179/excli2017-948.
75. Palimaka, S., Blackhouse, G. and Goeree, R. (2015) 'Colon capsule endoscopy for the detection of colorectal polyps: An economic analysis', *Ontario Health Technology Assessment Series*, 15(15), pp. 1–43.
76. Pang, Y. *et al.* (2018) 'Diabetes, plasma glucose and incidence of colorectal cancer in Chinese adults: A prospective study of 0.5 million people', *Journal of Epidemiology and Community Health*, 72(10), pp. 919–925. doi: 10.1136/jech-2018-210651.
77. Peeters, P. J. H. L. *et al.* (2015) 'The risk of colorectal cancer in patients with type 2 Diabetes: Associations with treatment stage and obesity', *Diabetes Care*, 38(3), pp. 495–502. doi: 10.2337/dc14-1175.
78. Price, S. and Wilson, L. (2016) *Patofisiologi Konsep Klinis dan Proses-Proses Penyakit*. 6th edn. Jakarta: Penerbit Buku KEdokteran EGC.
79. Purnomo, H. D. *et al.* (2023) 'Colorectal cancer screening in Semarang, Indonesia: A multicenter primary health care based study', *PLoS ONE*, 18(1 January), pp. 1–12. doi: 10.1371/journal.pone.0279570.
80. Rashid, Z. A. and Bardaweel, S. K. (2023) 'Novel Matrix Metalloproteinase-9 (MMP-9) Inhibitors in Cancer Treatment', *International Journal of Molecular Sciences*, 24(15). doi: 10.3390/ijms241512133.
81. Rawla, P., Sunkara, T. and Barsouk, A. (2019) 'Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors', *Przegląd Gastroenterologiczny*, 14(2), pp. 89–103. doi: 10.5114/pg.2018.81072.
82. Sawicki, T. *et al.* (2021) 'A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis', *Cancers*, 13(9), pp. 1–23. doi: 10.3390/cancers13092025.
83. Schreuders, E. H. *et al.* (2015) 'Colorectal cancer screening: A global overview of existing programmes', *Gut*, 64(10), pp. 1637–1649. doi: 10.1136/gutjnl-

2014-309086.

84. Sehgal, R. *et al.* (2014) 'Lynch Syndrome: An updated review', *Genes*, 5(3), pp. 497–507. doi: 10.3390/genes5030497.
85. Shussman, N. and Wexner, S. D. (2014) 'Colorectal polyps and polyposis syndromes', *Gastroenterology Report*, 2(1), pp. 1–15. doi: 10.1093/gastro/got041.
86. Siena, S. *et al.* (2009) 'Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer', *Journal of the National Cancer Institute*, 101(19), pp. 1308–1324. doi: 10.1093/jnci/djp280.
87. Sung, H. *et al.* (2021) 'Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries', *CA: A Cancer Journal for Clinicians*, 71(3), pp. 209–249. doi: 10.3322/caac.21660.
88. Thélin, C. and Sikka, S. (2015) 'Epidemiology of Colorectal Cancer — Incidence, Lifetime Risk Factors Statistics and Temporal Trends', *Screening for Colorectal Cancer with Colonoscopy*, (Table 1). doi: 10.5772/61945.
89. Valle, L. *et al.* (2019) 'Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine', *J Pathol*, 247(5), pp. 574–588. doi: 10.1002/path.5229.
90. Vinikoor, L. C. *et al.* (2007) 'Cholecystectomy and the risk of recurrent colorectal adenomas', *Cancer Epidemiology Biomarkers and Prevention*, 16(7), pp. 1523–1525. doi: 10.1158/1055-9965.EPI-07-0243.
91. Win, A. K. *et al.* (2012) 'Risk prediction models for colorectal cancer: A review', *Cancer Epidemiology Biomarkers and Prevention*, 21(3), pp. 398–410. doi: 10.1158/1055-9965.EPI-11-0771.
92. Winer, A., Adams, S. and Mignatti, P. (2018) 'Matrix metalloproteinase inhibitors in cancer therapy: Turning past failures into future successes', *Molecular Cancer Therapeutics*, 17(6), pp. 1147–1155. doi: 10.1158/1535-7163.MCT-17-0646.
93. Wong, M. C. S. *et al.* (2021) 'Differences in Incidence and Mortality Trends of Colorectal Cancer Worldwide Based on Sex, Age, and Anatomic Location', *Clinical Gastroenterology and Hepatology*, 19(5), pp. 955-966.e61. doi:

10.1016/j.cgh.2020.02.026.

94. World Health Organisation (2020) *World Health Statistics 2020: Monitoring Health for the SDGs, Sustainable Development Goals*. Available at: <https://all3dp.com/2/fused-deposition-modeling-fdm-3d-printing-simply-explained/>.
95. Yang, B. *et al.* (2014) 'Matrix metalloproteinase-9 overexpression is closely related to poor prognosis in patients with colon cancer', *World Journal of Surgical Oncology*, 12(1), pp. 1–6. doi: 10.1186/1477-7819-12-24.
96. Yang, J. *et al.* (2020) 'American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in familial adenomatous polyposis syndromes', *Gastrointestinal Endoscopy*, 91(5), pp. 963-982.e2. doi: 10.1016/j.gie.2020.01.028.
97. Young, P. E. *et al.* (2014) 'Early detection of colorectal cancer recurrence in patients undergoing surgery with curative intent: Current status and challenges', *Journal of Cancer*, 5(4), pp. 262–271. doi: 10.7150/jca.7988.
98. Zhang, Y. *et al.* (2017) 'Cholecystectomy can increase the risk of colorectal cancer: A meta-analysis of 10 cohort studies', *PLoS ONE*, 12(8), pp. 1–17. doi: 10.1371/journal.pone.0181852.
99. Zheng, S. *et al.* (2023) 'Effectiveness of Colorectal Cancer (CRC) Screening on All-Cause and CRC-Specific Mortality Reduction: A Systematic Review and Meta-Analysis', *Cancers*, 15(7). doi: 10.3390/cancers15071948.